Evkeeza
What Evkeeza is used for
Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Evkeeza
- Active substance
- evinacumab
- Disease area
- Hypercholesterolemia
- Medicine group
- Lipid modifying agents
- ATC code
- C10AX
- Marketing authorisation holder
- Ultragenyx Germany GmbH
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Evkeeza used for?
Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
What is the active substance in Evkeeza?
Evkeeza contains evinacumab.
Who makes Evkeeza?
The EU marketing authorisation holder is Ultragenyx Germany GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU